These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 33650737)

  • 21. Equitable and Effective Distribution of the COVID-19 Vaccines - A Scientific and Moral Obligation.
    Binagwaho A; Mathewos K; Davis S
    Int J Health Policy Manag; 2022 Feb; 11(2):100-102. PubMed ID: 33949818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expertise as a Response to Limited Multilateralism: The Case of South Korea's Vaccine Procurement Task Force for COVID-19 Vaccines amid Unequal Access via the COVAX Facility.
    Park J
    J Health Polit Policy Law; 2024 Feb; 49(1):99-132. PubMed ID: 37522333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap.
    Borges LC; Zeferino de Menezes H; Crosbie E
    Int J Health Policy Manag; 2022 Dec; 11(12):3101-3113. PubMed ID: 36028975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delayed Access to COVID-19 Vaccines: A Perspective on Low-income Countries in Africa.
    Hassan MA; Aliyu S
    Int J Health Serv; 2022 Jul; 52(3):323-329. PubMed ID: 35469499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 Vaccines: How Efficient and Equitable Was the Initial Vaccination Process?
    Das JK; Chee HY; Lakhani S; Khan MH; Islam M; Muhammad S; Bhutta ZA
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Charity or empowerment? The role of COVAX for low and middle-income countries.
    Holzer F; Roa TM; Germani F; Biller-Andorno N; Luna F
    Dev World Bioeth; 2023 Mar; 23(1):59-66. PubMed ID: 35307947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the institutional landscape and proliferation of proposals for global vaccine equity for COVID-19: too many cooks or too many recipes?
    Geiger S; McMahon A
    J Med Ethics; 2023 Aug; 49(8):583-590. PubMed ID: 34848492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future.
    Pilkington V; Keestra SM; Hill A
    Front Public Health; 2022; 10():821117. PubMed ID: 35321196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Access to COVID-19 vaccines and testing in Africa: the importance of COVAX - Nigeria as a case study.
    Grenfell RFQ; Oyeyemi OT
    Pathog Glob Health; 2023 Mar; 117(2):152-166. PubMed ID: 35770309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Access to COVID-19 vaccines: looking beyond COVAX.
    The Lancet
    Lancet; 2021 Mar; 397(10278):941. PubMed ID: 33714374
    [No Abstract]   [Full Text] [Related]  

  • 32. The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.
    Cernuschi T; Malvolti S; Hall S; Debruyne L; Bak Pedersen H; Rees H; Cooke E
    Vaccine; 2024 Apr; 42 Suppl 1(Suppl 1):S64-S72. PubMed ID: 38103962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Collaboration within the global vaccine safety surveillance ecosystem during the COVID-19 pandemic: lessons learnt and key recommendations from the COVAX Vaccine Safety Working Group.
    Chandler RE; Balakrishnan MR; Brasseur D; Bryan P; Espie E; Hartmann K; Jouquelet-Royer C; Milligan J; Nesbitt L; Pal S; Precioso A; Takey P; Chen RT;
    BMJ Glob Health; 2024 Mar; 9(3):. PubMed ID: 38453518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. WHO's allocation framework for COVAX: is it fair?
    Sharma S; Kawa N; Gomber A
    J Med Ethics; 2022 Jul; 48(7):434-438. PubMed ID: 33837046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. European collaborations on medicine and vaccine procurement.
    Vogler S; Haasis MA; van den Ham R; Humbert T; Garner S; Suleman F
    Bull World Health Organ; 2021 Oct; 99(10):715-721. PubMed ID: 34621089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.
    Wouters OJ; Shadlen KC; Salcher-Konrad M; Pollard AJ; Larson HJ; Teerawattananon Y; Jit M
    Lancet; 2021 Mar; 397(10278):1023-1034. PubMed ID: 33587887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brief communication International cooperation in a non-ideal world: the example of COVAX.
    Luna F; Holzer F
    Cad Iberoam Direito Sanit; 2021; 10(3):199-210. PubMed ID: 34938817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccine inequity: a threat to Africa's recovery from COVID-19.
    Wei CR; Kamande S; Lang'at GC
    Trop Med Health; 2023 Dec; 51(1):69. PubMed ID: 38111032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries.
    Peacocke EF; Heupink LF; Frønsdal K; Dahl EH; Chola L
    BMJ Open; 2021 Sep; 11(9):e049505. PubMed ID: 34593496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adopting an heterologous prime-boost strategy in COVID-19 vaccination: the need for locally generated evidence in Africa.
    Oboh MA; Omoleke S; Salami K
    Pan Afr Med J; 2022; 41():148. PubMed ID: 35519174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.